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Introduction: the rationale behind the Distaflo graft is inhibition of myointimal hyperplasia through optimisation of
haemodynamic forces at the distal anastomosis. This prospective study reports our early clinical results.
Method: patients with critical limb ischaemia, but no autologous vein, underwent infrainguinal bypass using Distaflo.
Clinical and Duplex assessment provided prospective data from which one year cumulative patency, limb salvage and
survival rates were calculated using Kaplan±Meier analysis. Log rank test enabled comparison with an historical control
group of Miller cuff grafts.
Results: fifty Distaflo were inserted over 29 months into 46 patients, median age 68.5 years, 27 male (59%), of which 27
(54%) were re-do procedures. Proximal anastomoses were to common femoral arteries in 40 cases (80%); distal anastomoses
were to popliteal vessels in 20 (40%), and tibial vessels in 30 (60%). The Distaflo graft had patency, limb salvage and
survival rates of 39, 50 and 82% respectively compared to 49, 56 and 85% respectively in the control group, with no
statistical difference (p 0.39; 0.65; 0.67 respectively; log rank).
Conclusion: in this non-randomised study, the Distaflo has similar one year patency, limb salvage and survival rates to the
Miller cuff, potentially justifying its use an alternative in distal prosthetic arterial reconstruction for critical limb
ischaemia.
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Introduction
The improved patency rates of an infragenicular Miller
cuff over an end-to-side prosthetic graft anastomosis
has been attributed, in part at least, to the presence of
the unique vortical flow pattern which increases wall
shear stress (WSS) at critical points within the anasto-
mosis, namely the heel, toe and along the recipient
artery floor.1±3 There is strong evidence supporting an
inverse relationship between WSS and the develop-
ment of myointimal hyperplasia (MIH), and the
rationale behind the Distaflo graft is optimisation of
haemodynamic forces at the distal anastomosis, there-
by inhibiting occlusive MIH.4±9 The vortex, deemed to
be beneficial in the Miller cuff, has been shown to be
replicated in the majority of in vivo Distaflo grafts,
which are now widely used as an alternative to inter-
position vein in the treatment of critical limb ischae-
mia.9 There remains, however, no clinical data upon
the outcome of the Distaflo graft.
The aim of this study was to report the short-term
outcome of the Distaflo graft and to explore whether it
offers a valid alternative to the interposition of vein
in the treatment of critical limb ischaemia at our
institution.
Patients and Methods
The Distaflo graft was introduced into our clinical
practice in January 1999, replacing the routine inter-
position of vein with femorodistal PTFE bypass. This
study was initiated upon insertion of the first graft,
and was carried out prospectively on an intention to
treat basis. Inclusion criteria were patients presenting
with critical limb ischaemia, as classified by the
Second European consensus 1992,10 suitable for infra-
inguinal arterial reconstruction on the basis of clinical
and intra-arterial digital subtraction angiographical
(IADSA) examination, and consenting to inclusion
into the study. In keeping with guidelines set out by
the TransAtlantic Inter-Society Consensus (TASC) on
the treatment of critical limb ischaemia, arterial
lesions amenable to radiological interventions, and
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autologous ipsilateral great saphenous or basilico-
cephalic arm vein of adequate quality constituted
exclusion criteria.11 Regional ethical approval for the
study was gained.
Recognised techniques for exposure of the arteries
and tunnelling of grafts were employed, with 5000
Units of intravenous Heparin routinely infused intra-
operatively. Evidence does not support routine post-
operative anticoagulation after prosthetic bypass,
although all patients were discharged on anti-platelet
medication.
The study group comprised of a consecutive series
of 50 Distaflo grafts, over 29 months. Patient demo-
graphics, pathophysiological parameters and anasto-
motic levels are summarised in Tables 1 and 2. Follow
up included Duplex assessment and clinical review,
and provided one year outcome measures including
cumulative graft patency, limb salvage and patient
survival, expressed as Kaplan±Meier survival curves.
Interrogation of the audit database at our institution
enabled the compilation of an historical control group
of infrainguinal Miller cuff grafts (Tables 1 and 2) for
the 5-year period immediately prior to the introduc-
tion of the Distaflo graft. Matching for age, gender,
risk factors and disease severity was attempted. This
was performed manually with the selector, UJK,
blinded to outcome measures to avoid introducing
bias. Statistical comparison between survival curves
was made using log rank tests, p5 0.05 representing
significance (SPSS for Windows release 10, Chicago,
Illanois, U.S.A.).
Results
Twenty-two bypass operations were performed
urgently within 7 days of acute admission (44%), 21
were elective (42%) and seven were emergencies within
24 h of admission (14%). Patients had a median
American Society of Anaesthesiology score of three.
Twenty-seven were re-do operations (54%), with a
total of 48 ipsilateral bypass procedures having been
undertaken in these limbs. The proximal anastomosis
was to the common femoral artery in 40 cases (80%)
with the remainder from either the external iliac or the
superficial femoral artery. The distal anastomosis
involved a crural vessel in 30 bypass procedures
(60%) and a popliteal artery in 20 reconstructions
(40%).
Immediate post-operative complications included
haemorrhage and/or haematoma in four patients,
anaemia in three, renal, cardiac or pulmonary failure
in four, proven myocardial infarction in three and
wound dehiscence in a single patient. Three patients
required return to theatre to resolve a complication.
The 30-day mortality was 4% (two patients) both of
whom had fatal myocardial infarctions. The overall
mortality was 18% (nine patients) representing 82%
one year survival on life table analysis (mean 748
days; 95% CI 654±843).
A total of 28 grafts occluded (56%), representing 3, 6
and 12 months cumulative patency rates of 67, 49 and
39% respectively (mean 311 days; 95% CI 207±416).
Secondary procedures included re-exploration,
thrombectomy or thrombolysis in six bypasses,
removal of three infected grafts, revision of a single
distal anastomosis and two re-do procedures. Twenty-
three limbs were deemed unsalvageable and under-
went amputation.
This decision was based on clinical judgement by
the surgeon and subjective input from the patient.
Nine amputations were below knee (39%) and 14
above knee (61%), of which two were below knee
conversions. Kaplan±Meier life table analysis gave 3,
6 and 12 months limb salvage rates of 74, 59 and 50%
respectively.
Comparison between the Distaflo group and an
historical control group of Miller cuff bypass grafts
Table 1. Patient demographics and clinical features in the Distaflo
and Miller cuff groups.
Distaflo Miller cuff
Total 50 50
Patients 46 47
Limbs 47 49
Male: female 1.4: 1 1.9: 1
Median age (range) 68.5 yrs (40±90) 67 yrs (45±86)
Diabetes 16 (35) 9 (19)
Rest pain 46 (92) 46 (92)
Necrosis 26 (52) 28 (56)
Primary procedure 23 (46) 24 (48)
Re-do procedure 27 (54) 26 (52)
1 previous procedure 16 (32) 15 (30)
41 previous procedure 11 (22) 11 (22)
Total previous procedures 48 41
Single run-off vessel 31 (62) 28 (56)
Percentages quoted in parentheses.
Table 2. Distal anastomotic vessel.
Distal vessel Distaflo Miller cuff
Above knee popliteal 7 (14) 2 (4)
Below knee popliteal 13 (26) 17 (34)
Anterior tibial 12 (24) 12 (24)
Tibio-peroneal trunk 3 (6) 1 (2)
Posterior tibial 7 (14) 8 (16)
Peroneal 8 (16) 10 (20)
Total infragenicular 30 (60) 31 (62)
Percentages quoted in parentheses.
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this study provides the first short-term clinical data on
the Distaflo graft, its power is limited by the incorp-
oration of an historical control. We felt this necessary
in order to set the data in context. The relatively low
numbers of prosthetic distal reconstructions under-
taken annually by a single institute would mean that
a randomised controlled trial comparing the Distaflo
with the Miller cuff would need to be multi-centred,
and run over several years. The early unpublished,
but presented data from such a trial in North America
concur with our finding of no statistical difference
between the two groups.18
One advantage of the new graft is the high conform-
ability of the thinned PTFE in the `` cuff'' which results
in improved handling, allowing successful completion
of the distal anastomoses in an often hostile anatom-
ical environment. Although the length of arteriotomy
required for the Distaflo is greater than that recom-
mended for a Miller cuff, the precuffed graft obviates
the need to harvest and create a vein cuff, thereby
simplifying the operation.9,19 In a group of patients
with a high rate of co-morbidity this can only be of
benefit, although similar mortality rates were noted in
our two groups.
There is no evidence of a clinical benefit in using a
Miller cuff to the above knee popliteal artery, however
the pathophysiological principles of MIH accretion
still apply, and therefore its use is not contra-
indicated.1,20 The improved handling properties of
vein and Distaflo alike have meant that in both groups
the surgeon has, on occasion, preferentially used these
techniques over an end-to-side anastomosis in order
to improve the technical profile of the anastomosis.
This has contributed to the heterogeneity of our study
groups however the relatively low numbers do not
facilitate stratification by distal anastomotic level.
The strong evidence supporting the use of vein for
infragenicular reconstruction introduces a heavy bias
into any study of femorodistal prosthetic graft per-
formance, as a high proportion of the operations are
redo procedures.21,22 More than half of our patients
had previously undergone at least one ipsilateral
bypass, and over one-fifth had two or more previous
procedures, and as such represent a group at the more
severe end of the disease spectrum. This may be
reflected in the steep descent of the patency and limb
salvage curves over the first 6 months of graft life.
Panayiotopoulos et al. described a `` Taylor score''
based on clinical and radiological parameters that
provided a prognostic score for predicting outcome
of femorodistal bypass grafts. In their series they
reported 100% graft failure at 10 months in those
patients scoring in the lowest group. When such a
score was applied to our Distaflo group, 40% scored
in this worst category, and yet nearly a fifth of these
grafts were still patent at one year. Although no sci-
entific conclusion can be drawn from this, it demon-
strates some success in adverse conditions and
potentially supports our aggressive policy for recon-
struction to achieve limb salvage.
In conclusion, this study suggests that, in the
absence of vein, the Distaflo graft may offer an alter-
native in prosthetic femorodistal arterial reconstruc-
tion, with similar cumulative patency, limb salvage
and survival rates to the Miller cuff. Results of a
randomised control trial are required before more
definitive conclusions can be made.
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